secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2024-10-07T23:59:59+00:00
Accession:  0001213900-24-085921
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Capital Acquisition receives Nasdaq deficiency notice for non-compliance with listing rules
--------------------------------------------------------------------------------

- Nasdaq notified Denali on Oct 2, 2024 of non-compliance with MVLS ($50M minimum) and Total Assets rules for Nasdaq Global Market.
- Company has 180 days, until March 31, 2025, to regain compliance by meeting MVLS >= $50M for 10 consecutive business days.
- No immediate delisting; securities continue trading on Nasdaq; management is evaluating options to regain compliance.
- Failure to comply by deadline may result in a delisting notice with opportunity to appeal to a Nasdaq Hearing Panel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000121390024085921/0001213900-24-085921-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000121390024085921/ea0216758-8k425_denali.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-085921

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer